Literature DB >> 28397326

Diagnosis and management of neuropathies associated with plasma cell dyscrasias.

Evan Rosenbaum1, Douglas Marks1, Shahzad Raza1.   

Abstract

Neuropathies associated with plasma cell dyscrasias are a major cause of morbidity for patients managed by medical oncologists. Because of similarities in clinical presentation and on nerve conduction studies, identifying the underlying disease leading to a paraproteinemic neuropathy can often be difficult. In addition, the degree of neurologic deficit does not strictly correlate with the extent of abnormalities on common clinical laboratory testing. Fortunately, with increasing understanding into the biologic mechanisms of underlying hematologic diseases, additional biomarkers have recently been developed, thus improving our diagnostic capacity. Neuropathies associated with plasma cells dyscrasias are seen with Monoclonal gammopathy of undetermined significance (MGUS) particularly IgM subtype, followed by IgG and IgA MGUS, multiple myeloma, Waldenström's macroglobulinemia, amyloid, Castleman's disease, and POEMS syndrome. The mechanisms of neuronal injury associated with plasma cell dyscrasia vary based on underlying diagnosis and include malignant infiltration, immune-mediated antibody deposition, or local compression of nerve roots. The polyneuropathies are frequently demyelinating, although axonal and mixed neuropathies can also be seen. As demonstrated by the cases included in this review, patients frequently present with symmetric sensory disturbance, followed by progressive motor weakness. Unfortunately, because of the complexity of diagnostic testing, patients are frequently examined late, often after receiving several ineffective therapies. The aim of this case-based review is to provide clinicians with insight on how to properly recognize these atypical neuropathies and send the appropriate diagnostic work, increasing the likelihood of accurately classify the patient's underlying hematologic disorder.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  MGUS; POEMS; Waldenstrom Macroglobulinemia; amyloidosis; multiple myeloma; neuropathy

Mesh:

Year:  2017        PMID: 28397326     DOI: 10.1002/hon.2417

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  4 in total

Review 1.  Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.

Authors:  M Hasib Sidiqi; Morie A Gertz
Journal:  Blood Cancer J       Date:  2021-05-15       Impact factor: 11.037

Review 2.  Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.

Authors:  Morie A Gertz
Journal:  Blood Cancer J       Date:  2018-05-23       Impact factor: 11.037

3.  [Anti-myelin-associated glycoprotein antibody positive IgM monoclonal gammopathy related peripheral neuropathy: 11 cases and literature review].

Authors:  X M Gao; M N Jia; M Qian; H T Ren; L Zhang; K N Shen; X X Cao; J Li
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-11-14

4.  High prevalence of peripheral neuropathy in multiple myeloma patients and the impact of vitamin D levels, a cross-sectional study.

Authors:  B E Oortgiesen; J A Kroes; P Scholtens; J Hoogland; P Dannenberg-de Keijzer; C Siemes; F G A Jansman; R E Kibbelaar; N J G M Veeger; M Hoogendoorn; E N van Roon
Journal:  Support Care Cancer       Date:  2021-07-17       Impact factor: 3.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.